Alnylam Pharmaceuticals Announces the Termination of its RNAi Collaboration with Merck
News Sep 20, 2007
Alnylam Pharmaceuticals, has announced that Merck & Co., Inc. ("Merck") and Alnylam have mutually agreed to terminate their July 2006 amended and restated RNAi agreement.
As a result, Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership's former co-development programs.
"It is fundamentally in our best interests to terminate our Merck collaboration," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "We wish our colleagues at Merck the best of luck in their efforts."
The American Society of Human Genetics (ASHG), along with several co-signing organizations, issued a position statement today outlining whether, and to what extent, there is a responsibility to recontact genetic and genomic research participants when new findings emerge that suggest their genetic information should be interpreted differently, which would allow participants to benefit from current genomics advances.READ MORE